Arcus Biosciences Bundle
Who owns Arcus Biosciences?
When Gilead expanded its collaboration with Arcus between 2020–2023, committing over $1.5 billion, ownership became central to Arcus’s clinical and commercial trajectory. Arcus (NASDAQ: RCUS) was founded in 2015 and focuses on next‑generation cancer immunotherapies.
As of 2024–2025 Arcus remains publicly traded with institutional public float, notable strategic stakes from Gilead, and founder/insider holdings shaping governance and partnerships; see Arcus Biosciences Porter's Five Forces Analysis.
Who Founded Arcus Biosciences?
Founders and Early Ownership of Arcus Biosciences trace to 2015 when medicinal chemists Terry J. Rosen, PhD, and Juan C. Jaen, PhD, co-founded the company and held concentrated founder equity with typical four-year vesting and one-year cliffs; their combined stake was a meaningful minority pre-IPO and was diluted through subsequent financings.
Founding team structure
Rosen served as CEO and Jaen as President, sharing control in a standard co-founder split and governance arrangement.
Founder equity terms
Founder stock and options used a four-year vesting schedule with a one-year cliff to align long-term incentives.
Early employee grants
Equity packages targeted senior drug-development talent to build preclinical and early clinical teams.
Seed and pre-IPO investors
Institutional biotech VCs and crossover specialists led 2016–2017 rounds; friends-and-family stakes were minimal.
Investor rights
Early investors held protective provisions, pro rata and registration rights ahead of the 2018 IPO.
Governance and co-sale
Buy-sell and co-sale provisions were conventional, permitting clean follow-on financings without governance stalemates.
Pre-IPO SEC filings and the S-1 indicated founders and early institutional backers remained prominent among Arcus Biosciences shareholders, though exact initial percentages were not itemized; by the IPO in 2018 the cap table showed significant dilution from multiple private rounds and registration of shares for public trading.
Key facts on founders and early ownership
Founders retained executive roles through IPO and maintained insider ownership that declined post-financings; institutional investors acquired the largest aggregate stakes.
- Founders: Terry J. Rosen, PhD (CEO) and Juan C. Jaen, PhD (President)
- Vesting: standard four-year vesting with one-year cliffs for founder equity
- Financing timeline: seed and pre-IPO rounds in 2016–2017, IPO in 2018
- Early investor rights: protective provisions, pro rata, and registration rights
For a deeper look at market positioning and shareholder implications tied to early ownership dynamics see Target Market of Arcus Biosciences.
Arcus Biosciences SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Arcus Biosciences’s Ownership Changed Over Time?
Key events reshaping Arcus Biosciences ownership include the March 15, 2018 IPO, Gilead’s multi-year strategic collaboration and equity purchases from 2020–2024, and institutional consolidation from 2021–2025 that shifted the register toward passive and healthcare-specialist funds.
| Year / Event | Ownership Impact |
|---|---|
| 2018 IPO (Mar 15, 2018) | Raised roughly $120–$140 million (priced at $13), implied market cap near $600–$700 million; increased institutional float and diluted founders/early investors. |
| 2020–2023 Gilead strategic collaboration | Gilead invested via private placements, upfronts, option fees, and R&D co-funding; by 2023–2024 held a double-digit percentage stake (teens), becoming the largest strategic shareholder. |
| 2021–2025 institutional consolidation | Large passive and active managers accumulated shares as TIGIT data emerged; institutions collectively held the majority of the float by late 2024/early 2025 (typical peer ranges 80%+ institutional float). |
Current major stakeholders include Gilead Sciences as the strategic minority investor, large passive funds such as BlackRock and Vanguard among top holders, active healthcare/crossover funds, and insiders (founders/executives/board) whose combined equity and option holdings remain in the single digits.
Ownership dynamics and governance implications
Gilead’s equity stake plus program options materially changed Arcus’s financing and development risk profile while institutional ownership concentrated voting power around clinical and cash-runway milestones.
- Who owns Arcus Biosciences: mix of strategic (Gilead), passive (BlackRock, Vanguard), active healthcare funds, and minority insiders.
- Arcus Biosciences ownership: institutions hold the majority of float; insiders collectively single-digit ownership.
- Arcus Biosciences shareholders: Gilead cited in filings as the largest strategic shareholder (teens %); top institutional holders frequently include BlackRock, Vanguard, State Street, Wellington, Fidelity.
- For deeper context see Revenue Streams & Business Model of Arcus Biosciences
Arcus Biosciences PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Arcus Biosciences’s Board?
As of 2024–2025, Arcus Biosciences' board blends founders and independent biotech operators: Terry J. Rosen (CEO) and Juan C. Jaen (President) sit on the board alongside independent directors with clinical development, BD, and commercial expertise, while strategic partners hold observer rights rather than board control.
| Director | Role/Expertise | Notes |
|---|---|---|
| Terry J. Rosen | CEO / Corporate strategy | Founder-executive; board member |
| Juan C. Jaen | President / Operations | Executive director; development & commercialization |
| Independent Directors | Clinical dev, BD, commercial | Bring institutional governance experience |
| Strategic Partner Representatives | Observer/designate | Collaboration alignment; not majority controllers |
Voting is one-share-one-vote common stock; Arcus does not use a dual-class or super-voting structure and discloses no golden share or special voting rights, so influence derives from economic stakes and collaboration agreements rather than preferential voting.
Board composition and voting overview
Board makeup reflects founders plus independent biotech operators; major shareholders exercise influence via stake size and agreements, not special votes.
- Board includes executives Terry J. Rosen and Juan C. Jaen
- One-share-one-vote common stock; no dual-class shares
- Gilead and other institutional investors are large shareholders but no controlling vote
- Recent shareholder votes focused on equity plans, share authorizations, and director elections
Major institutional holders reported in 2024–2025 include mutual funds and asset managers typically listed in 13F filings; insider ownership (executives and directors) commonly ranges in low single-digit percentages collectively, while strategic partners may hold mid-single-digit to low-double-digit stakes—see the detailed institutional breakdown and governance analysis in Marketing Strategy of Arcus Biosciences.
Arcus Biosciences Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Arcus Biosciences’s Ownership Landscape?
Recent trading volatility and institutional repositioning have reshaped who owns Arcus Biosciences between 2022 and 2025, with strategic investor Gilead retaining an anchor stake while follow-on financings and ATMs modestly adjusted the public float and insider percentages.
| Period | Ownership/Action |
|---|---|
| 2022–2023 | Multiple domvanalimab and adenosine-pathway readouts drove trading; institutions increased positions; Gilead established/maintained strategic stake via collaboration milestones and option exercises. |
| 2023–2024 | Arcus completed selective follow-on offerings and ATM sales to fund Phase 2/3 programs, modestly diluting insiders/public holders; no large buybacks; cash runway extended toward 2026–2027. |
| 2024–2025 | Institutional ownership rose with sector reacceleration; activist scrutiny increased industry-wide but Arcus avoided high-profile contests; Gilead continued incremental equity adjustments tied to collaborations. |
Institutional leadership in the register persisted, founders and insiders remained minority holders, and potential future catalysts—TIGIT registrational outcomes, ex‑US commercialization options, or expanded strategic investments—could shift the Arcus Biosciences ownership mix.
Capital actions and dilution
Follow-on financings and targeted ATM usage supported R&D; these moves diluted public and insider stakes but preserved cash for Phase 2/3 programs through 2026–2027.
Strategic investor role
Gilead acted as anchor strategic investor, exercising options and funding collaborations that provided non-dilutive capital components alongside equity adjustments tied to milestones.
Ownership trends vs. peers
Arcus mirrored clinical-stage peers: rising institutional holdings as rates stabilized and M&A reaccelerated; no privatization signals, and activist campaigns did not target the company prominently.
Potential future shifts
Registrational data for TIGIT combos, expanded ex‑US licensing or further strategic equity infusions (notably from Gilead or partners) are key catalysts that could change the Arcus Biosciences shareholders composition.
For a deeper look at strategy and partnership context that shapes Arcus Biosciences ownership dynamics, see Growth Strategy of Arcus Biosciences
Arcus Biosciences Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Arcus Biosciences Company?
- What is Competitive Landscape of Arcus Biosciences Company?
- What is Growth Strategy and Future Prospects of Arcus Biosciences Company?
- How Does Arcus Biosciences Company Work?
- What is Sales and Marketing Strategy of Arcus Biosciences Company?
- What are Mission Vision & Core Values of Arcus Biosciences Company?
- What is Customer Demographics and Target Market of Arcus Biosciences Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.